Tags

Type your tag names separated by a space and hit enter

Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion.
Ophthalmic Res. 2014; 51(3):153-60.OR

Abstract

PURPOSE

To explore functional and morphological retinal changes 6 months after dexamethasone intravitreal implant (DEX implant) for the treatment of macular edema due to central or branch retinal vein occlusion (CRVO, BRVO).

PROCEDURES

In this prospective interventional case series patients underwent a complete ophthalmological examination at baseline and monthly, including best-corrected visual acuity (BCVA), spectral domain-optical coherence tomography and microperimetry. Fluorescein angiography was performed at baseline and at 4 months. All patients were treated with a DEX implant and retreated according to predefined criteria starting from month 4.

RESULTS

Sixteen patients (mean age 66 ± 13 years, 14 CRVO, 2 BRVO) were included. At 6 months mean retinal sensitivity improved from 9.7 ± 4.6 to 13.6 ± 5.4 dB (p < 0.0001) while mean BCVA improved from 52.4 ± 16.2 to 66.1 ± 16.6 (p < 0.0001). Mean central retinal thickness decreased from 708.3 ± 151.01 to 362.7 ± 177.4 μm (p < 0.0001); 56.2% of eyes were retreated at month 4.

CONCLUSIONS

At 6 months DEX implant led to a significant improvement in retinal sensitivity and visual acuity associated with a reduction of retinal thickness in patients with macular edema due to retinal vein occlusion.

Authors+Show Affiliations

Fondazione G.B. Bietti, IRCCS, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24642474

Citation

Parravano, Mariacristina, et al. "Exploring the Morphological and Functional Retinal Changes After Dexamethasone Intravitreal Implant (Ozurdex®) in Macular Edema Due to Retinal Vein Occlusion." Ophthalmic Research, vol. 51, no. 3, 2014, pp. 153-60.
Parravano M, Oddone F, Boccassini B, et al. Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Ophthalmic Res. 2014;51(3):153-60.
Parravano, M., Oddone, F., Boccassini, B., Giorno, P., Chiaravalloti, A., Tedeschi, M., Scarinci, F., & Varano, M. (2014). Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Ophthalmic Research, 51(3), 153-60. https://doi.org/10.1159/000357275
Parravano M, et al. Exploring the Morphological and Functional Retinal Changes After Dexamethasone Intravitreal Implant (Ozurdex®) in Macular Edema Due to Retinal Vein Occlusion. Ophthalmic Res. 2014;51(3):153-60. PubMed PMID: 24642474.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. AU - Parravano,Mariacristina, AU - Oddone,Francesco, AU - Boccassini,Barbara, AU - Giorno,Paola, AU - Chiaravalloti,Adele, AU - Tedeschi,Massimiliano, AU - Scarinci,Fabio, AU - Varano,Monica, Y1 - 2014/03/13/ PY - 2013/09/11/received PY - 2013/11/11/accepted PY - 2014/3/20/entrez PY - 2014/3/20/pubmed PY - 2014/10/25/medline SP - 153 EP - 60 JF - Ophthalmic research JO - Ophthalmic Res VL - 51 IS - 3 N2 - PURPOSE: To explore functional and morphological retinal changes 6 months after dexamethasone intravitreal implant (DEX implant) for the treatment of macular edema due to central or branch retinal vein occlusion (CRVO, BRVO). PROCEDURES: In this prospective interventional case series patients underwent a complete ophthalmological examination at baseline and monthly, including best-corrected visual acuity (BCVA), spectral domain-optical coherence tomography and microperimetry. Fluorescein angiography was performed at baseline and at 4 months. All patients were treated with a DEX implant and retreated according to predefined criteria starting from month 4. RESULTS: Sixteen patients (mean age 66 ± 13 years, 14 CRVO, 2 BRVO) were included. At 6 months mean retinal sensitivity improved from 9.7 ± 4.6 to 13.6 ± 5.4 dB (p < 0.0001) while mean BCVA improved from 52.4 ± 16.2 to 66.1 ± 16.6 (p < 0.0001). Mean central retinal thickness decreased from 708.3 ± 151.01 to 362.7 ± 177.4 μm (p < 0.0001); 56.2% of eyes were retreated at month 4. CONCLUSIONS: At 6 months DEX implant led to a significant improvement in retinal sensitivity and visual acuity associated with a reduction of retinal thickness in patients with macular edema due to retinal vein occlusion. SN - 1423-0259 UR - https://www.unboundmedicine.com/medline/citation/24642474/Exploring_the_morphological_and_functional_retinal_changes_after_dexamethasone_intravitreal_implant__Ozurdex®__in_macular_edema_due_to_retinal_vein_occlusion_ L2 - https://www.karger.com?DOI=10.1159/000357275 DB - PRIME DP - Unbound Medicine ER -